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In the original publication of this article \[[@CR1]\], there is a mistake in Fig. [4](#Fig1){ref-type="fig"}e.

The corrected Fig. [4](#Fig1){ref-type="fig"}e should be: Fig. 1Upregulation of ST6GAL1 promotes proliferation and chemoresistance in T-ALL cell lines (**a**) qRT-PCR and western blot were carried out to detect ST6GAL1 levels. **b** The expression of FITC-SNA was dertermined. **c** The viability of cells transfected with ST6GAL1 was determined by CCK8 assay at 0, 24, 48, 72 and 96 h. **d** Enhanced ST6GAL1 facilitated colony formation. **e** Ki67 expression was observed by immunoflourescence, red fluorescence: Ki67, blue fluorescence: DAPI. **f** CCK8 assays were used to measure the resistance to ADR, VCR and Pacliatxel. The absorbance was measured at 450 nm. **g** The IC50 values were calculated. **h** Relative molecular expression of key caspase-dependent apoptosis was analyzed by western blot. **i** The apoptosis rate of different treated cells was analyzed by FCM. ST6GAL1 upregulation inhibited cells survival in response to ADR. j Effects of ST6GAL1 upregulation on tumor growth were shown in vivo. **k** ST6GAL1 and Ki67 expression was observed by IHC staining. Data were means ± SD of triplicate determinants (\**P* \< 0.05)
